Penumbra, Inc. (PEN): Price and Financial Metrics

Penumbra, Inc. (PEN)

Today's Latest Price: $203.21 USD

2.04 (-0.99%)

Updated Dec 3 11:45am

Add PEN to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 143 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

PEN Stock Summary

  • PEN's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 519.18 -- higher than 93.23% of US-listed equities with positive expected earnings growth.
  • PEN's price/sales ratio is 13.83; that's higher than the P/S ratio of 88.46% of US stocks.
  • Over the past twelve months, PEN has reported earnings growth of -148.58%, putting it ahead of only 13.32% of US stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Penumbra Inc, a group of peers worth examining would be QBAK, SGH, ELSE, THR, and CUB.
  • PEN's SEC filings can be seen here. And to visit Penumbra Inc's official web site, go to

PEN Stock Price Chart Interactive Chart >

Price chart for PEN

PEN Price/Volume Stats

Current price $203.21 52-week high $277.00
Prev. close $205.24 52-week low $121.80
Day low $190.16 Volume 1,020,256
Day high $206.72 Avg. volume 345,792
50-day MA $227.56 Dividend yield N/A
200-day MA $196.81 Market Cap 7.38B

Penumbra, Inc. (PEN) Company Bio

Penumbra Inc. is a specialty interventional therapies company that develops and markets innovative medical devices to treat challenging medical conditions with significant unmet clinical needs. The company was founded in 2004 and is based in Alameda, CA.

PEN Latest News Stream

Event/Time News Detail
Loading, please wait...

PEN Latest Social Stream

Loading social stream, please wait...

View Full PEN Social Stream

Latest PEN News From Around the Web

Below are the latest news stories about Penumbra Inc that investors may wish to consider to help them evaluate PEN as an investment opportunity.

Nikola’s Milton will end up in jail for “fraud”: Whitney Tilson

Whitney Tilson’s email to investors discussing Enrique Abeyta on CNBC; Stick a fork in Nikola Corporation (NASDAQ:NKLA); Short report on Brookfield Property Partners; Carson Block and GSX Techedu; Penumbra’s Catheter Fail; Theranos’ Holmes May Pursue ‘Mental Disease’ Defense. Q2 2020 hedge fund letters, conferences and more 1) My colleague Enrique Abeyta was on CNBC last […] The post Nikola’s Milton will end up in jail for “fraud”: Whitney Tilson appeared first on ValueWalk .

ValueWalk | September 15, 2020

Worldwide Brain Aneurysm Treatment Industry to 2027 - Featuring Mizuho Medical, Penumbra & Medtronic Among Others -

DUBLIN--(BUSINESS WIRE)--The "Brain Aneurysm Treatment Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Type; Condition; End User, and Geography" report has been added to's offering. The brain aneurysm treatment market was valued at US$ 2,184.15 million in 2019 and is expected to grow at a CAGR of 14.1% from 2020 to 2027 to reach US$ 6,222.47 million by 2027. Driving factors of the brain aneurysm treatment market are increasing prevalence of brain aneurysm

Business Wire | August 25, 2020

The Daily Biotech Pulse: Adcom Rules In Favor Of Mesoblast, CureVac IPO, Novavax Clinches UK COVID-19 Vaccine Deal

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 13) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Fulgent Genetics Inc (NASDAQ: FLGT ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Inozyme Pharma Inc (NASDAQ: INZY ) iTeos Therapeutics Inc (NASDAQ: ITOS ) Mirati Therapeutics Inc (NASDAQ: MRTX ) Natera Inc (NASDAQ: NTRA ) Nurix Therapeutics Inc (NASDAQ: NRIX ) Orthopediatrics Corp (NASDAQ: KIDS ) Penumbra Inc (NYSE: PEN ) Rocket Pharmaceuticals Inc (NASDAQ: RCKT ) Silk Road Medical Inc (NASDAQ: SILK ) TFF Pharmaceuticals Inc (NASDAQ: TFFP ) Vaxcyte Inc (NASDAQ: PCVX ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 13) Entera Bio Ltd (NASDAQ: ENTX ) Forma Therapeutics Holdings Inc (NASDAQ: FMTX )(reacted to its second-quarter results) L...

Benzinga | August 14, 2020

Penumbra, Inc. (PEN) CEO Adam Elsesser on Q2 2020 Results - Earnings Call Transcript

Penumbra, Inc. (PEN) Q2 2020 Earnings Conference Call August 3, 2020 4:30 PM ET Company Participants Jee Hamlyn-Harris - Investor Relations Adam Elsesser - Chairman and Chief Executive Officer Maggie Yuen - Chief Financial Officer Conference Call Participants Bob Hopkins - Bank of America Cecilia Furlong - Canaccord Genuity Larry...

SA Transcripts on Seeking Alpha | August 4, 2020

The Daily Biotech Pulse: Merck's Breakthrough Therapy Designation, Sonoma Surges On Sanitizer News, Sanofi-Glaxo And More

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) Axonics Modulation Technologies Inc (NASDAQ: AXNX ) Capricor Therapeutics Inc (NASDAQ: CAPR ) Fulgent Genetics Inc (NASDAQ: FLGT ) ITAMAR MED LTD/S ADR (NASDAQ: ITMR ) Medpace Holdings Inc (NASDAQ: MEDP ) (saw an extension of its earnings-induced momentum) NeoGenomics, Inc. (NASDAQ: NEO )(reacted to its second-quarter results) OncoSec Medical Inc (NASDAQ: ONCS ) Penumbra Inc (NYSE: PEN ) Qiagen NV (NYSE: QGEN ) TFF Pharmaceuticals Inc (NASDAQ: TFFP ) Trevena Inc (NASDAQ: TRVN ) X T L Biopharmaceuticals Ltd (NASDAQ: XTLB ) Zoetis Inc (NYSE: ZTS ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 28) Nkarta Inc (NASDAQ: NKTX ) Nurix Therapeutics Inc (NASDAQ: NRIX )(IPOed Friday) Verrica Pharmaceuticals Inc (NASDAQ:...

Benzinga | July 29, 2020

Read More 'PEN' Stories Here

PEN Price Returns

1-mo -18.62%
3-mo -1.55%
6-mo 13.50%
1-year 17.50%
3-year 103.52%
5-year 308.54%
YTD 23.70%
2019 34.43%
2018 29.86%
2017 47.49%
2016 18.57%
2015 N/A

Continue Researching PEN

Here are a few links from around the web to help you further your research on Penumbra Inc's stock as an investment opportunity:

Penumbra Inc (PEN) Stock Price | Nasdaq
Penumbra Inc (PEN) Stock Quote, History and News - Yahoo Finance
Penumbra Inc (PEN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.725 seconds.